A postmarketing all-case surveillance of mogamulizumab in patients with CCR4 positive relapsed or refractory adult T cell lymphoma-leukemia

Trial Profile

A postmarketing all-case surveillance of mogamulizumab in patients with CCR4 positive relapsed or refractory adult T cell lymphoma-leukemia

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Dec 2016

At a glance

  • Drugs Mogamulizumab (Primary)
  • Indications T cell lymphoma; T-cell leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 26 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top